** Shares of Shanghai Junshi Biosciences Co Ltd surge 10.1% to HK$12.26, their highest since Aug. 23, on course for the second consecutive session of gain
** Stock on track for the biggest one-day pct rise since April 9; sixth biggest pct gainer in healthcare index , which rises 2.3%
** Company says European Commission has approved for marketing of toripalimab for treatment of metastatic nasopharyngeal carcinoma, or a malignant tumor in epithelium of the nasopharynx which is common types of head and neck cancers
** Says the approval is applicable to all 27 member states of the European Union, Iceland, Norway and Liechtenstein
** Shanghai-listed stock rises 4% to 25.39 yuan, highest since Sept. 13
** Hang Seng Commerce & Industry Index adds 1.4% and Hang Seng Index rises 1.6%
** Hong Kong stock dropped 42.7% YTD, Shanghai shares down 41.6% YTD
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.